Skip to main content
SpringerLink
Log in

Spironolactone treatment in patients with diabetic microalbuminuria and resistant hypertension

  • Original Article
  • Published:
International Journal of Diabetes in Developing Countries Aims and scope Submit manuscript

Abstract

Resistant hypertension is common in diabetes. Spironolactone by inhibiting aldosterone not only exerts antihypertensive effect but also antiproteinuric effect. In this study, the mean decrease in systolic and diastolic blood pressure after 4 weeks of spironolactone was 25.5 ± 7.8 and 11.4 ± 3.5 mmHg respectively and it increased further at 8 weeks and at 12 weeks, while there was no significant change in blood pressure in the control group. At 12 weeks, significantly greater reductions in both the systolic and diastolic blood pressure were observed in patients treated with spironolactone having serum potassium less than 4 meq/l vs those having serum potassium more than 4 meq/l. Reduction in urine microalbumin, though higher in patients with serum potassium less than 4 meq/l was not significant at any intervals.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Kotchen TA. Hypertensive vascular disease. In: Fauci SA, Kasper DL, Longo DL, Braunwald E, Hauser SL, Jameson JL, et al. editors. Harrison’s Principles of Internal Medicine, 17th edition; 2008. Pp- 1549–1562.

  2. Calhoun DA, Zaman MA, Nishizaka MK. Resistant hypertension. Curr Hypertens Rep. 2002;4:221–8.

    Article  PubMed  Google Scholar 

  3. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure. Hypertension. 2003;42:1206–52.

    Article  PubMed  CAS  Google Scholar 

  4. UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS 38. BMJ. 1998;317:703–13.

    Article  Google Scholar 

  5. Arauz-Pacheco C, Parrott MA, Raskin P. Treatment of hypertension in adults with diabetes. Diabetes Care. 2003;26 Suppl 1:S80–2.

    PubMed  Google Scholar 

  6. The GISEN group. Randomized placebo controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric nondiabetic nephropathy. Lancet. 1997;349:1857–63.

    Article  Google Scholar 

  7. The ACE inhibitors in Diabetic Nephropathy Trialist Group. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin converting enzyme inhibitors? A metaanalysis of individual patient data. Ann Intern Med. 2001;134:370–179.

    Google Scholar 

  8. Brenner BM, Cooper ME. deZeeuw D, et al. Effect of losartan on renal and cardiovascular outcomes in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:861–9.

    Article  PubMed  CAS  Google Scholar 

  9. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Eng J Med. 2001;345:851–60.

    Article  CAS  Google Scholar 

  10. Epstein M. Aldosterone as a mediator of progressive renal disease; pathogenetic and clinical implications. Am J Kidney Dis. 2001;37:677–88.

    Article  PubMed  CAS  Google Scholar 

  11. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309–21.

    Article  PubMed  CAS  Google Scholar 

  12. Mancia G, Laurent S, Agabiti-Rosei E, et al. European society of Hypertension. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens. 2009;27:2121–58.

    Article  PubMed  CAS  Google Scholar 

  13. Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low dose spironolactone in subjects with resistant hypertension. Am J Hypertens. 2003;16:925–30.

    Article  PubMed  CAS  Google Scholar 

  14. Abolghasmi R, Taziki O. Efficacy of low dose spironolactone in chronic kidney disease with resistant hypertension. Saudi J Kidney Dis Transplant. 2011;22:75–8.

    Google Scholar 

  15. Lane DA, Shah S, Beevers DG. Low dose spironolactone in the management of resistant hypertension; a surveillance study. J Hypertens. 2007;25:891–4.

    Article  PubMed  CAS  Google Scholar 

  16. Xue C, Siragy HM. Local renal aldosterone system and its regulation by salt, diabetes and angiotensin II type 1 receptor. Hypertension. 2005;46:584–90.

    Article  PubMed  CAS  Google Scholar 

  17. Wehling M, Spes CH, Win N, et al. Rapid cardiovascular action of aldosterone in man. J Clin Endocrinol Metab. 1998;83:3517–22.

    Article  PubMed  CAS  Google Scholar 

  18. Chapman N, Dobson J, Wilson S, Dahlof B, Server PS, Wedel H, Poulter NR, on behalf of the Anglo Scandinavian Cardiac Outcomes Trial Investigation. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension. 2007;49:839–45.

    Article  PubMed  CAS  Google Scholar 

  19. Goodfriend TL. Treating resistant hypertension with a neglected old drug. Hypertension. 2007;49:763–4.

    Article  PubMed  CAS  Google Scholar 

  20. Mahmud A, Feely J. Aldosterone to rennin ratio, arterial stiffness and the response to aldosterone antagonism in essential hypertension. Am J Hypertens. 2005;18:50–5.

    Article  PubMed  CAS  Google Scholar 

  21. Mahmud A, Mahgoub M, Hall M, Feely J. Does aldosterone to rennin ratio predict the antihypertensive effect of aldosterone antagonist spironolactone? Am J Hypertens. 2005;18:1631–5.

    Article  PubMed  CAS  Google Scholar 

  22. Bianchi S, Bigassi R, Compere VM. Antagonists of aldosterone and proteinuriain patients with CKD: an uncontrolled pilot study. Am J Kidney Dis. 2005;46:45–51.

    Article  PubMed  CAS  Google Scholar 

  23. Sato A, Hayashi K, Naruse M, Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension. 2003;41:64–8.

    Article  PubMed  CAS  Google Scholar 

  24. Nitta K, Uchida K, Nihei H. Spironolactone and angiotensin receptor blocker in non diabetic renal disease. Am J Med. 2004;117:44–445.

    Article  Google Scholar 

  25. Sica DA. Eplerenone and serum potassium change relationship to renal function. Am J Hypertens. 2003;16:A100.

    Article  Google Scholar 

Download references

Acknowledgements

All the authors would extend their heartfelt thanks to Dr Jagadeesh Tangudu, MS, PhD, Sowmya Jammula for their immense and selfless contribution towards manuscript preparation, language editing and final approval of text.

Author information

Authors and Affiliations

  1. Department of Endocrinology, Medwin Hospital, Room- 258, Raghava Ratna Towers, Chirag Ali Lane, Nampally, Hyderabad, 500001, Andhra Pradesh, India

    Sunil Kumar Kota & Kirtikumar D. Modi

  2. Department of Pharmaceutics, Roland Institute of Pharmaceutical Sciences, Khodasingi, Ambapua, Berhampur, 760010, Orissa, India

    Sruti Jammula

  3. Department of Anaesthesia, Central Security Hospital, C/O- AMISAL, Xenel building, Dabab street, Near Tamimi Market, PO Box- 3886, Riyadh, 11481, Saudi Arabia

    Siva Krishna Kota

  4. Department of Medicine, MKCG Medical College, Berhampur, 760004, Orissa, India

    Lalit Kumar Meher

Authors
  1. Sunil Kumar Kota
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sruti Jammula
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Siva Krishna Kota
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lalit Kumar Meher
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kirtikumar D. Modi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sunil Kumar Kota.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kota, S.K., Jammula, S., Kota, S.K. et al. Spironolactone treatment in patients with diabetic microalbuminuria and resistant hypertension. Int J Diabetes Dev Ctries 32, 33–36 (2012). https://doi.org/10.1007/s13410-012-0063-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13410-012-0063-5

Keywords

Search

Navigation